Longevity Health Holdings added 44,382 common shares to a prospectus while issuing a $416,667 10% senior secured convertible note due February 29, 2028. Investors get defined disclosure of potential Equity issuance, secured Debt terms and Warrant changes, including a $1.38 exercise price and 712,307 shares issuable.
Key Highlights
- Puritan Partners LLC is the purchaser and Collateral agent for the secured convertible note.
- The note proceeds are designated for Working Capital subject to an August 13, 2026 settlement agreement.
- Warrants issued January 2, 2025 will have an exercise price of $1.38 and 712,307 shares issuable upon exercise.
Longevity Health Holdings, Inc. (OTC: XAGE) is supplementing its prospectus to cover 44,382 shares of common stock and a $416,667 senior secured convertible note. The note creates a direct financial obligation and is due February 29, 2028.
10% Convertible Note and Prospectus Terms
The supplement amends the prospectus dated June 5, 2024, which forms part of registration statement No. 333-279329. The note carries a 10% rate and was issued to Puritan Partners LLC. The note and common stock issuable upon conversion were sold without Securities Act registration under Section 4(a)(2) and/or Rule 506 of Regulation D, based in part on Puritan’s accredited-investor representations. No general solicitation or Advertising was used.
Collateral, Guarantees and Warrant Adjustments
Collateral terms include an amended and restated security agreement and a separate intellectual-property security agreement, each naming Puritan Partners LLC as collateral agent. Longevity Health will use the note proceeds for working capital, subject to the settlement agreement dated August 13, 2026. The transaction also changes warrants issued January 2, 2025, reducing the exercise price from $3.3557 to $1.38 and increasing shares issuable upon exercise from 292,929 to 712,307.
FAQs
Q: What is the stock impact of Longevity Health’s convertible note?
A: The note is convertible into common stock and creates a direct financial obligation of $416,667. The supplement covers 44,382 shares of common stock.
Q: Which Longevity Health warrant terms changed?
A: Warrants issued January 2, 2025 will have an exercise price reduced from $3.3557 to $1.38. Shares issuable upon exercise increase from 292,929 to 712,307.
Q: How will Longevity Health use the note proceeds?
A: The company will use the note proceeds for working capital. That use is subject to the settlement agreement dated August 13, 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.